Cancer Advisor

Abstract Background: Cancer has traditionally been conceptualized as a genetic disease driven by somatic mutations. Increasing evidence, however, suggests that metabolic dysregulation—including altered mitochondrial function, glucose metabolism, and systemic hormonal signaling—plays a critical role in tumor initiation and progression. Objective: To review the current evidence supporting metabolic interventions in cancer care, including dietary strategies, repurposed drugs, nutraceuticals, and lifestyle modifications, and to evaluate their role as adjuncts to standard oncologic therapies. Methods: A narrative review was conducted synthesizing preclinical studies, observational data, and clinical trials (where available) related to metabolic approaches in oncology, including ketogenic diets, fasting protocols, insulin-modulating agents, and repurposed pharmacologic agents. Results: Metabolic interventions demonstrate heterogeneous levels of evidence. Lifestyle interventions such as p...

Abstract Lung cancer remains the leading cause of cancer mortality worldwide despite rapid progress in precision oncology and immunotherapy. The year 2025 marked a convergence of advances across molecular diagnostics, artificial intelligence–driven pathology, novel targeted and immune-based therapeutics, and increased interest in real-world drug repurposing strategies. Alongside regulatory approvals of next-generation targeted agents and bispecific immunotherapies, observational data have emerged describing the off-label use of antiparasitic agents—fenbendazole, ivermectin, and mebendazole—as adjunctive interventions in lung cancer. This integrative review synthesizes validated clinical and translational advances with mechanistic and real-world observations on repurposed anthelmintics, critically appraising their biological plausibility, evidence limitations, and implications for future research. The analysis highlights the widening gap between innovation and evidence generation, under...

A b s t r a c t B a c k g r o u n d : Stage 4 colorectal cancer (CRC) has poor prognosis, driven by cancer stem cells (CSCs). Repurposed drugs (ivermectin, mebendazole) with supplements and a ketogenic diet show promise in targeting CSC pathways. O b j e c t i v e : To evaluate   integrative multimodal protocol  (including high-dose oral ivermectin (1 mg/kg 3x/week, escalating to 1.5 mg/kg for non-responders), mebendazole (100 mg twice daily), IV vitamin C, oral vitamin D, oral zinc, ketogenic diet, and intermittent fasting) vs. FOLFOX or placebo in virtual patients with stage 4 CRC. M e t h o d s : An in silico RCT simulated 1,000 patients randomized to three arms. Molecular docking (AutoDock Vina), molecular dynamics (GROMACS), and pharmacokinetic/pharmacodynamic (PK/PD) modeling (Simcyp) assessed drug-target interactions. Primary endpoint: OS at 12 months; secondary end...